# Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

> **NCT02291237** · PHASE2,PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 172 (actual)

## Conditions studied

- Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Eleclazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02291237
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-05
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-02-17
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291237, "Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT02291237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*